Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.85 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.63 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | TYR | P14679 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL31006937 | 1.00 | TSHR (0.85) | TSHRCYP3A4NFKB1BLMPMP22 | |
| Sulfuric Acid SCHEMBL31254117 | 1.00 | TSHR (0.85) | TSHRCYP3A4NFKB1BLMPMP22 | |
| SCHEMBL31254086 | 0.92 | TSHR (1.00) | TSHRCYP3A4NFKB1BLMPMP22 | |
| SCHEMBL31364250 | 0.92 | TSHR (1.00) | TSHRCYP3A4NFKB1BLMPMP22 | |
| SCHEMBL31254076 | 0.92 | TSHR (1.00) | TSHRCYP3A4NFKB1BLMPMP22 | |
| SCHEMBL29776919 | 0.92 | TSHR (1.00) | TSHRCYP3A4NFKB1BLMPMP22 | |
| SCHEMBL43536 | 0.92 | TSHR (1.00) | TSHRCYP3A4NFKB1BLMPMP22 | |
| Piperazine SCHEMBL31187001 | 0.84 | CYP3A4 (0.82) | TSHRCYP3A4NFKB1BLMPMP22 | |
| SCHEMBL29397450 | 0.82 | NFKB1 (0.60) | TSHRCYP3A4NFKB1BLMPMP22 | |
| SCHEMBL28709318 | 0.82 | NFKB1 (0.60) | TSHRCYP3A4NFKB1BLMPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113711029-A | Method for the diagnostic and/or prognostic evaluation of chronic plus acute liver failure syndrome in patients suffering from liver disorders | 欧洲慢性肝衰竭研究基金会 | 2021-11-26 | — | — | CN | claimed |
| WO-2020159321-A2 | METHOD FOR ASSESSING MEDICINAL EFFECT OF THERAPEUTIC AGENT FOR NEUROPSYCHIATRIC DISORDERS BY USING MICRODIALYSIS AND SIMULTANEOUS ANALYSIS OF VARIOUS NEUROTRANSMITTERS IN PRIMATES | 주식회사 뉴로비스 | 2020-08-06 | — | — | WO | claimed |
| WO-2017189528-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | Ecolab USA, Inc. (US) | 2017-11-02 | — | — | WO | claimed |
| US-20170306504-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | CHAMPIONX LLC | 2017-10-26 | — | — | US | claimed |
| CN-122005638-A | Jerusalem artichoke extract and application thereof in resisting inflammation and regulating intestinal flora and metabolites thereof | 西北农林科技大学 | 2026-05-12 | — | — | CN | disclosed |
| CN-118976090-A | Traditional Chinese medicine composition for treating parkinsonism and application thereof | 湖南省中医药研究院 | 2024-11-19 | — | — | CN | disclosed |
| JP-2023109096-A | NEUROBLASTOMA DETECTION METHOD AND NEUROBLASTOMA BIOMARKERS | 国立大学法人 東京大学 | 2023-08-07 | — | — | JP | disclosed |
| CN-111595987-B | Metabolic marker related to pulmonary hypertension in heart failure progression process and application | 深圳大学 | 2022-07-08 | — | — | CN | disclosed |
| CN-113711029-A | Method for the diagnostic and/or prognostic evaluation of chronic plus acute liver failure syndrome in patients suffering from liver disorders | 欧洲慢性肝衰竭研究基金会 | 2021-11-26 | — | — | CN | disclosed |
| CN-111595987-A | Metabolic marker related to pulmonary hypertension in heart failure progression process and application | 深圳大学 | 2020-08-28 | — | — | CN | disclosed |
| WO-2020159321-A2 | METHOD FOR ASSESSING MEDICINAL EFFECT OF THERAPEUTIC AGENT FOR NEUROPSYCHIATRIC DISORDERS BY USING MICRODIALYSIS AND SIMULTANEOUS ANALYSIS OF VARIOUS NEUROTRANSMITTERS IN PRIMATES | 주식회사 뉴로비스 | 2020-08-06 | — | — | WO | disclosed |
| US-20190391092-A1 | METABOLIC PROFILING WITH MAGNETIC RESONANCE MASS SPECTROMETRY (MRMS) | Oregon Institute of Science and Medicine | 2019-12-26 | — | — | US | disclosed |
| US-4377595-A | TYROSINE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1983-03-22 | — | — | US | disclosed |
| EP-0005333-B1 | A PHARMACEUTICAL COMPOSITION COMPRISING AN AMINO ACID FOR REDUCING BLOOD SERUM PROLACTIN LEVELS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1982-04-07 | — | — | EP | disclosed |
| US-4296119-A | ADMINISTERING TRYPTOPHAN AS TYROSINE PRECURSER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1981-10-20 | — | — | US | disclosed |
| US-4237135-A | ANTIDEPRESSANTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 1980-12-02 | — | — | US | disclosed |
| US-4224343-A | TYROSINE AND/OR PHENYLALANINE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1980-09-23 | — | — | US | disclosed |
| EP-0005333-A1 | A pharmaceutical composition comprising an amino acid for reducing blood serum prolactin levels | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1979-11-14 | — | — | EP | disclosed |
| EP-0005057-A1 | A material and composition for reducing blood pressure | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1979-10-31 | — | — | EP | disclosed |
| EP-0005058-A2 | Composition for regulating dopamine or norepinephrine levels in neuronal synapses | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1979-10-31 | — | — | EP | disclosed |